| Literature DB >> 29434117 |
Azimun Nahar1, Sharda Prasad Awasthi1, Noritoshi Hatanaka1, Kentaro Okuno1, Phuong Hoai Hoang1,2, Jayedul Hassan1, Atsushi Hinenoya1, Shinji Yamasaki1.
Abstract
The purpose of this study was to investigate the prevalence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-Ec) in retail chicken meats in Japan. Fifty-six domestic and 50 imported (Brazil, n=36; United States, n=8; Thailand, n=6) chicken meat samples were analyzed. The 162 ESBL-Ec included 111 from 43 (77%) domestic samples and 51 from 26 (52%) Brazilian samples. Fifty-three and 30 of 111 and 51 ESBL-Ec from domestic and Brazilian chickens, respectively, were selected for ESBL genotyping. The blaCTX-M (91%), blaTEM (36%) and blaSHV (15%) genes were detected in ESBL-Ec isolated from domestic chickens, whereas blaCTX-M (100%) and blaTEM (20%) were detected in ESBL-Ec isolated from imported chickens. Among the blaCTX-M group, blaCTX-M-2 (45%) and blaCTX-M-1 (34%) were prevalent in domestic chicken isolates, whereas blaCTX-M-2 (53%) and blaCTX-M-8 (43%) were prevalent in imported chicken isolates. Domestic chicken isolates were mostly resistant to tetracycline (83%), followed by streptomycin (70%) and nalidixic acid (62%). Imported chicken isolates were resistant to streptomycin (77%), followed by nalidixic acid (63%) and tetracycline (57%). Notably, extensive multidrug resistance was detected in 60% (32/53) and 70% (21/30) ESBL-Ec from domestic and imported chickens, respectively. Virulence genes associated with diarrheagenic and extra-intestinal pathogenic E. coli were detected in ESBL-Ec isolated from domestic and imported chickens. These data suggest that ESBL-Ec in retail chicken meats could be a potential reservoir for antimicrobial resistance determinants and that some are potentially harmful to humans.Entities:
Keywords: E. coli; ESBL; domestic chicken; imported chicken; virulence genes
Mesh:
Substances:
Year: 2018 PMID: 29434117 PMCID: PMC5880835 DOI: 10.1292/jvms.17-0708
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Isolation of ESBL-producing E. coli (ESBL-Ec) from retail chicken meats
| Origin | Country of origin | No. of | No. (%) of ESBL-Ec positive samples | Total no. of ESBL-Ec isolates |
|---|---|---|---|---|
| Domestic (n=56) | Japan (56) | 54 | 43 (77) | 111 |
| Imported (n=50) | Brazil (36) | 36 | 26 (72) | 51 |
| U.S.A. (8) | 5 | 0 (0) | 0 | |
| Thailand (6) | 1 | 0 (0) | 0 | |
| Sub total | 42 | 26 (52) | 51 | |
| Total | 138 | 69 (65) | 162 | |
Prevalence of ESBL genotypes in ESBL-producing E. coli isolated from retail chicken meats
| ESBL genotypes | No. of isolates (%) | ||
|---|---|---|---|
| Domestic (n=53) | Imported (n=30) | ||
| 48 (91) | 30 (100) | ||
| 18 (34) | 1 (3.3) | ||
| 24 (45) | 16 (53) | ||
| 1 (1.9) | 13 (43) | ||
| 5 (9.4) | 0 (0) | ||
| 19 (36) | 6 (20) | ||
| 8 (15) | 0 (0) | ||
Antimicrobial resistance of ESBL-producing E. coli isolated from retail chicken meats
| Antimicrobial agents | No. of resistant isolates (%) | |
|---|---|---|
| Domestic (n=53) | Imported (n=30) | |
| AMPa) | 53 (100) | 30 (100) |
| FOXb) | 2 (3.7) | 0 (0) |
| CTXc) | 53 (100) | 30 (100) |
| CAZd) | 10 (19) | 1 (3.3) |
| IPMe) | 0 (0) | 0 (0) |
| STR f) | 37 (70) | 23 (77) |
| KANg) | 31 (58) | 12 (40) |
| GENh) | 0 (0) | 0 (0) |
| CIPi) | 13 (25) | 8 (27) |
| NALj) | 33 (62) | 19 (63) |
| TETk) | 44 (83) | 17 (57) |
| CHLl) | 18 (34) | 6 (20) |
| FOSm) | 2 (3.8) | 0 (0) |
| SXTn) | 27 (51) | 15 (50) |
a) ampicillin, b) cefoxitin, c) cefotaxime, d) ceftazidime, e) imipenem, f) streptomycin, g) kanamycin, h) gentamicin, i) ciprofloxacin, j) nalidixic acid, k) tetracycline, l) chloramphenicol, m) fosfomycin, n) sulfamethoxazole-trimethoprim.
Multidrug resistance pattern in ESBL-producing E. coli isolated from retail chicken meats
| Domestic | Imported | ||||
|---|---|---|---|---|---|
| NRa) | MDR patternb) | NIc) | NRa) | MDR patternb) | NIc) |
| 8 | AMP, CTX, STR, KAN, CIP, NAL, TET, CHL, SXT | 7 | 8 | AMP, CTX, STR, KAN, CIP, NAL, TET, CHL, SXT | 1 |
| AMP, CTX, STR, KAN, NAL, TET, CHL, FOS, SXT | 1 | AMP, CTX, STR, CIP, NAL, TET, CHL, SXT | 1 | ||
| AMP, CTX, STR, KAN, CIP, NAL, TET, FOS, SXT | 1 | 7 | AMP, CTX, KAN, CIP, NAL, CHL, SXT | 1 | |
| 7 | AMP, CTX, CAZ, STR, KAN, NAL, TET, CHL, SXT | 4 | AMP, CTX, STR, KAN, CIP, NAL, TET, SXT | 1 | |
| AMP, CTX, STR, KAN, NAL, TET, CHL, SXT | 3 | 6 | AMP, CTX, STR, NAL, CIP, TET | 3 | |
| AMP, CTX, FOX, CAZ, STR, CIP, NAL, TET, SXT | 1 | AMP, CTX, STR, KAN, NAL, TET, SXT | 1 | ||
| AMP, CTX, FOX, STR, NAL, TET, CHL, SXT | 1 | AMP, CTX, STR, KAN, CIP, NAL, TET | 1 | ||
| AMP, CTX, STR, NAL, TET, CHL, SXT | 1 | AMP, CTX, STR, NAL, TET, SXT | 1 | ||
| AMP, CTX, STR, KAN, CIP, NAL, TET, FOS | 1 | AMP, CTX, STR, NAL, TET, CHL | 1 | ||
| 6 | AMP, CTX, CAZ, STR, KAN, TET, CHL, SXT | 1 | 5 | AMP, CTX, STR, KAN, NAL, TET | 1 |
| AMP, CTX, CAZ, STR, NAL, TET, SXT | 1 | AMP, CTX, STR, KAN, NAL, SXT | 3 | ||
| AMP, CTX, STR, KAN, CIP, NAL, TET | 1 | AMP, CTX, KAN, TET, SXT | 1 | ||
| AMP, CTX, STR, NAL, TET, SXT | 3 | AMP, CTX, STR, KAN, TET, CHL | 1 | ||
| AMP, CTX, STR, CIP, NAL, TET | 1 | AMP, CTX, STR, NAL, SXT | 2 | ||
| 5 | AMP, CTX, STR, KAN, NAL, TET | 3 | AMP, CTX, STR, TET, SXT | 2 | |
| AMP, CTX, STR, KAN, TET, SXT | 2 | 4 | AMP, CTX, CAZ, NAL | 1 | |
| 4 | AMP, CTX, STR, KAN, TET | 3 | AMP, CTX, STR, KAN, TET | 1 | |
| AMP, CTX, NAL, TET | 2 | AMP, CTX, STR, SXT | 1 | ||
| AMP, CTX, KAN, TET | 1 | AMP, CTX, STR, TET | 1 | ||
| 3 | AMP, CTX, TET | 5 | AMP, CTX, STR, CHL | 1 | |
| AMP, CTX, CAZ, STR | 1 | 3 | AMP, CTX, NAL | 1 | |
| AMP, CTX, CAZ, KAN | 2 | 2 | AMP, CTX | 3 | |
| AMP, CTX, NAL | 1 | ||||
| 2 | AMP, CTX | 5 | |||
| AMP, CTX, CAZ | 1 | ||||
| Total | 53 | Total | 30 | ||
a) Number of antimicrobial resistance classes according to CLSI [8], b) AMP (ampicillin), FOX (cefoxitin), CTX (cefotaxime), CAZ (ceftazidime), STR (streptomycin), KAN (kanamycin), CIP (ciprofloxacin), NAL (nalidixic acid), TET (tetracycline), CHL (chloramphenicol), FOS (fosfomycin), SXT (sulfamethoxazole-trimethoprim), c) Number of isolates.
Distribution of phylogenetic groups of ESBL-producing E. coli isolated from retail chicken meats
| Phylogenetic group | No. of isolates (%) by origin | |
|---|---|---|
| Domestic (n=53) | Imported (n=30) | |
| A | 11 (21) | 7 (23) |
| B1 | 17 (32) | 6 (20) |
| B2 | 0 (0) | 1 (3.3) |
| D | 25 (47) | 16 (53) |
Prevalence of virulence genes in ESBL-producing E. coli isolated from retail chicken meats
| Origin | Prevalence of virulence genes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diarrheagenic genes (%)a) | Extra intestinal pathogenic | ||||||||||
| Others | PAI | Others | |||||||||
| Domestic | 12 (23) | 0 (0) | 0 (0) | 10 (19) | 10 (19) | 6 (11) | 26 (49) | 5 (9) | 32 (60) | 9 (17) | 0 (0) |
| (n=53) | |||||||||||
| Imported | 14 (47) | 1 (3.3) | 0 (0) | 4 (13) | 4 (13) | 6 (20) | 13 (43) | 8 (27) | 29 (97) | 8 (27) | 0 (0) |
| (n=30) | |||||||||||
a) astA (enteroaggregative E. coli heat-stable enterotoxin 1), cdtB (cytolethal distending toxin), others [eaeA (E. coli-attaching and effacing), bfpA (bundle-forming pilus), elt (heat-labile enterotoxin), est (heat-stable enterotoxin), eagg (plasmid of enteroaggregative E. coli), stx1 (Shiga toxin 1), stx2 (Shiga toxin 2), invE (invasin of EIEC), daaD (fimbriae adhesion)], b) papEF, papC (pilus associated with pyelonephritis, P fimbriae, adhesion), fyuA (yersiniabactin receptor, siderophore), iroN (catecholate receptor, siderophore), kpsMT (capsular polysaccharide synthesis, protection and invasion), traT (serum survival associated, protection and invasion), PAI (pathogenicity-associated island marker), others [usp (uropathogenic-specific protein), ibeA (invasion of brain endothelium), sfa/focDE (S and F1C fimbriae, adhesion), afaBC (Dr antigen-specific adhesion operons), hlyA (hemolysin, toxin) and cnf (cytotoxic necrotizing factor, toxin)].
Distribution of virulence gene profile of ESBL-producing E. coli isolated from retail chicken meats
| Domestic | Imported | ||
|---|---|---|---|
| Virulence gene profilea) | NIb) | Virulence gene profilea) | NIb) |
| 1 | 3 | ||
| 2 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 2 | 3 | ||
| 2 | 1 | ||
| 2 | 2 | ||
| 3 | 2 | ||
| 3 | 1 | ||
| 2 | 1 | ||
| 1 | 2 | ||
| 1 | 3 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 6 | ||
| 3 | |||
| 9 | |||
| 2 | |||
| 4 | |||
| 4 | |||
| None | 6 | ||
| Total | 53 | Total | 30 |
a) astA (enteroaggregative E. coli heat-stable enterotoxin 1), cdtB (cytolethal distending toxin), papEF, papC (pilus associated with pyelonephritis, P fimbriae, adhesion), fyuA (yersiniabactin receptor, siderophore), iroN (catecholate receptor, siderophore), kpsMT (capsular polysaccharide synthesis, protection and invasion), traT (serum survival associated, protection and invasion), PAI (pathogenicity-associated island marker), b) Number of isolates.